Key result
HFA-PEFF screening identifies ~76% of heart failure outpatients as HFpEF, with high guideline-directed therapy uptake.
Why the study?
Chronic heart failure affects approximately 1.2 million individuals in Poland with substantial misdiagnosis due to comorbidities, motivating the collection of real-world data on ambulatory patients diagnosed with HFmrEF or HFpEF.
Cross-Sectional (n=500)
No
This real-world cross-sectional study of 500 Polish outpatients with HFpEF or HFmrEF demonstrates a predominance of the HFpEF phenotype (75.6%), high comorbidity burden, and near-universal adoption of SGLT2 inhibitors and finerenone.
Answers are grounded in this paper and cite their sources.
Real-world Polish data support HFA-PEFF applicability in HFmrEF/HFpEF; leaves open need for prospective validation before broader adoption.
INTRODUCTION: Chronic heart failure is a highly prevalent condition in aging populations. In Poland, it is estimated to affect approximately 1.2 million individuals, with a substantial number of cases being misdiagnosed, partly due to the presence of comorbidities. This cross-sectional, single-center study aimed to collect real-world data on ambulatory patients diagnosed with either heart failure with mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF). MATERIAL AND METHODS: Patients were screened for eligibility during routine outpatient visits using an integrated diagnostic pathway consistent with the Heart Failure Association's HFA-PEFF algorithm. Data included patient demographics, clinical characteristics, cardiovascular parameters, comorbidities, and pharmacotherapy. RESULTS: A total of 500 patients were included; nearly 70% were women. HFpEF was diagnosed in 75.6% of patients, whereas HFmrEF was identified in 24.4%. Most patients had hypertension (84.8%) and peripheral arterial disease (77.4%); and 23.8% of patients had type 2 diabetes. The mean left atrial volume index (LAVI) was 44.9 ± 19.1 mL/m2, and the mean E/e' ratio was 13.8 ± 5.4. Reduced renal function (eGFR < 60 mL/min/1.73 m2) was observed in 42% of patients. All participants received combination pharmacotherapy, most commonly finerenone (98.8%), beta-blockers (82.8%), and sodium-glucose cotransporter 2 inhibitors (SGLT2is) (98.6%); over half of all participants (59.8%) were treated with loop diuretics. CONCLUSIONS: The study provides valuable real-world data on patients with chronic heart failure at a single outpatient cardiology clinic in Poland, highlighting a predominance of the HFpEF phenotype, which is consistent with recent trends in heart failure diagnosis.
No takes yet. Share an insight, caveat, or question.
Szychta et al. (2026) conducted a cross-sectional in Heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction (HFmrEF) (n=500). HFpEF vs HFmrEF phenotype and routine outpatient pharmacotherapy was evaluated on Prevalence of HFpEF and HFmrEF phenotypes and clinical characteristics. Ambulatory heart failure outpatients screened via the HFA-PEFF pathway predominantly had HFpEF over HFmrEF, with high use of finerenone and SGLT2is.
Synapse has enriched 10 related papers. Consider them for comparative context: